Previous Article | Next Article ![]()
Molecular and Cellular Biology, October 2003, p. 6936-6943, Vol. 23, No. 19
0270-7306/03/$08.00+0 DOI: 10.1128/MCB.23.19.6936-6943.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Department of Molecular and Cellular Biology, Harvard University, Cambridge, Massachusetts 02138,1 Centre de Recherche en Cancérologie de l'Université Laval, L'Hôtel-Dieu de Québec, CHUQ, Québec, Canada G1R 2J62
Received 29 May 2003/ Accepted 16 June 2003
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Two additional Plks have been described in frog and mammalian cells. Plk2 and Plk3 (Fnk/Prk) were both identified as immediate-early transcripts in cultured murine fibroblasts (11, 47). Plk3 is expressed throughout the cell cycle, although its abundance increases from G1 to M phase, and it appears to be phosphorylated in M phase (4). On the other hand, Plk2 expression is detected only in G1, and endogenous Plk2 is rapidly turned over (36). Therefore, the expression of the three mammalian Plks during the cell cycle resembles the successive transition of the cyclins, prompting speculation that Plks may regulate the cell cycle in a manner analogous to that of Cdks (31). Although the role of Plk3 is not well characterized, there are reported functions for Plk3 in the cell cycle. For example, Plk3 phosphorylates and activates Cdc25C (39), and maturation of Xenopus oocytes was accelerated by microinjection of Plx3 mRNA and delayed by injection of a kinase-deficient mutant (12). Moreover, overexpression of Plk3 resulted in incomplete cytokinesis (5). Plk3 may also be involved in the DNA damage checkpoint, possibly through the p53 pathway (58). It is not clear, however, how some other reported functions of Plk3 fit into the cell cycle. One study suggested that Plk3 may be involved in cell adhesion in human macrophages (22), and the expression of Plk3 in rat brain appeared to correlate with neuronal activities (27). Recently, endogenous Plk3 was shown to localize to the centrosome, and overexpression of Plk3 induced changes in cell morphology (57).
Relatively few reports of the function of Plk2 have appeared. In the adult mouse, Plk2 expression is detected in the brain but not in proliferating tissues, such as the thymus or testis (47), and it was reported that the level of Plk2 in the brain is increased by stimuli that induce long-term potentiation (27). When ectopically expressed, Plk2 caused changes in cell morphology and, after an extended period of time, cell death (36). Plk2 was also shown to interact with the calcium- and integrin-binding protein CIB, which inhibits Plk2 kinase activity (36). Despite these data, the role of Plk2, and especially whether it is involved in the regulation of the cell cycle, remains elusive. To investigate the function of Plk2 in vivo, we generated mouse lines carrying a null mutation in the Plk2 gene. Analysis of the growth and development of Plk2-/- mice indicated that Plk2 is involved in embryonic development and cell cycle progression.
| MATERIALS AND METHODS |
|---|
|
|
|---|
|
Genotyping and analyses of Plk2 expression. Genomic DNA was isolated from ES cells as described previously (43). Isolation of genomic DNA from clipped mouse tails was performed with a lysis buffer containing 100 mM Tris-HCl, pH 8.5, 5 mM EDTA, 0.2% sodium dodecyl sulfate, 200 mM NaCl, and 1 mg of proteinase K (GIBCO BRL)/ml. PCR analysis was performed with three primers: p1 (5'-ATGGAGCTCCTGCGGAC-3'), p2 (5'-GTCTGTGAAGCTCGATTTC-3'), and p3 (5'-ATATTGCTGAAGAGCTTGGCGGC-3') (Fig. 1A). Cycling was for 45 s at 94°C, 1 min at 60°C, and 3 min at 72°C for 30 cycles with Taq DNA polymerase (Panvera). The PCR products were separated on 0.7% agarose gels and visualized by staining them with ethidium bromide. Southern and Northern blot analyses were performed using radiolabeled probes (Fig. 1A). The 5' probe, corresponding to Met-1 to Lys-123, was generated by PCR with primers 5'-ATGGAGCTCCTGCGGAC-3' and 5'-TCTTTTCCCTCTGATGAGG-3', and the 3' probe was the 1-kbp XbaI fragment from clone 2, corresponding to Leu-480 to Asn-682 (47). Total RNA was prepared from mouse brain using TRIZOL reagent (GIBCO BRL). Rapid amplification of cDNA ends by reverse transcription and PCR (RACE RT-PCR) analyses were performed according to the protocol for the 5' RACE system (GIBCO BRL), except that cDNA was purified by phenol extraction and ethanol precipitation. Plk2-specific cDNA was synthesized with primer 5'-TGCAGGAAGAAGTCATG-3' and amplified by PCR with the Upstream Amplification Primer (GIBCO BRL) and 5'-GAATGGAGGTCTTCCTAGCAG-3'. Sequencing of the 5' end of amplified cDNA was performed with primers 5'-CTGCCTGAGGTAGTATCG-3' and 5'-TTCACAGCCGTGTCCTTG-3'. Western blot analysis of Plk2 in nocodazole-treated embryonic fibroblasts was performed as described previously (36).
Weight study and histological examination. To normalize the conditions for the weight study, a total of 10 to 12 newborns were kept with two nursing mice before they were weaned. Tail clipping was carried out on day 7 after birth, and the pups were weaned on the 18th day. Embryos and placentas were dissected out of decidua and cleared of membranes and umbilical cords in PBS. After excess buffer was blotted with a paper towel, they were weighed on a Mettler PG503-S balance. For histology, tissues were fixed in Bouin's solution for 24 to 40 h and embedded in paraffin. Sections (5 µm thick) were made with a Reichert-Jung Supercut 2050 microtome, and staining with hematoxylin and eosin was performed according to standard procedures.
TUNEL assays and immunohistochemistry. Tissues were fixed in 4% paraformaldehyde overnight at 4°C and embedded in paraffin to make 5-µm-thick sections. Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) assays were performed with an ApopTag Red In Situ Detection kit (Serologicals Co.) according to the manufacturer's protocol. Immunohistochemistry with anti-phospho-histone H3 (Upstate Biotechnology) was carried out basically as described previously (59). Fluorescence confocal microscopy was performed as described previously (36). For cell counting, positive cells in each sample were justified with the area of the labyrinthine zone as calculated from hematoxylin- and eosin-stained sections.
Embryonic fibroblast cell culture and cell cycle analysis. Embryonic fibroblasts were derived from embryonic day 13.5 (E13.5) embryos as described previously (18). The cell suspension was plated onto one 15-cm-diameter tissue culture dish, and these were regarded as passage 1 cells. For cell cycle analysis, cells at passage 3 were incubated in Dulbecco's modified Eagle's medium plus 0.1% fetal bovine serum for 48 h. The cells were then incubated with normal growth medium and subjected to fluorescence-activated cell sorting (FACS) analysis as described previously (24). The study of cell proliferation over an extended time (48 h) was carried out using the protocol for studying 3T3 cell lines (54), except that 60-mm-diameter tissue culture plates were used.
| RESULTS |
|---|
|
|
|---|
Northern blot analysis of total RNA isolated from adult Plk2-/- mouse brain with a 3' Plk2 probe detected a low-abundance RNA that is shorter than the full-length Plk2 message (Fig. 1D, top). RACE RT-PCR was carried out to produce and amplify the 5' ends of cDNAs from the total mRNA, and sequencing of the 5' end with Plk2-specific probes revealed that the smaller RNA is indeed a truncated Plk2 message containing, from 5' to 3', sequence from the Neo cassette, Plk2 intron sequence immediately following the cassette, and sequence of the third exon of Plk2 (data not shown). This truncated Plk2 message did not hybridize to a 5' Plk2 probe that is upstream of the insertion site of the Neo cassette (Fig. 1D, middle). Therefore, the minor message appears to have originated from the Neo cassette, and it predicts a 59.2-kDa truncated Plk2 that does not have the first two kinase domains, including the conserved putative ATP-binding pocket that is necessary for Plk2 kinase activity (36). To examine whether any Plk2 is produced, fibroblasts derived from Plk2-/- embryos were treated with nocodazole, released into the cell cycle for 190 min, and analyzed by Western blotting with an antibody specific for the C terminus of Plk2. Our antibody failed to detect Plk2 in any tissue in wild-type animals; however, a prior study showed that the production of Plk2 in NIH 3T3 cells peaks at this time point (36). No full-length or truncated Plk2 was detected in Plk2-/- cells under these conditions (Fig. 1E). Altogether, these data suggest that our Plk2-/- mice are deficient in Plk2.
Growth of Plk2-/- mice. A summary of over 50 litters from heterozygous crosses showed that wild-type, heterozygous, and Plk2-/- mice were born at a ratio of 1:2:1, indicating that Plk2 deletion did not cause embryonic lethality (data not shown). However, Plk2-/- mice appeared smaller than other littermates, and their skin color was pale (Fig. 2A), although they did not appear to be anemic, because the color of their veins was similar to that in normal mice (Fig. 2A and B). About 30% of Plk2-/- mice were born with incompletely closed eyelids (Fig. 2B), but all Plk2-/- mice were viable. Adult Plk2-/- mice were fertile, with no anomaly detected in major tissues by histological examination (data not shown). Moreover, Plk2-/- and normal mice showed comparable 12-month survival rates (data not shown).
|
20% smaller than normal mice (0.05 < P < 0.1) (Fig. 2C). Starting from the third week, about the time when growth hormone takes effect, the weights of female and male mice were analyzed separately because their growth rates began to differ (13). The results showed that Plk2-/- mice were consistently smaller than normal mice (Fig. 2D). Comparison of weight gains shows that normal and Plk2-/- mice have practically the same growth rate (Fig. 2E), indicating that Plk2 is not required for postnatal growth and that the dwarfism of Plk2-/- mice is likely caused by defective embryonic development. Development of Plk2-/- embryos. To investigate whether disruption of Plk2 affected the overall progress of embryonic development, skeletal development was examined by staining with alcian blue and alizarin red. Bone development in the mouse follows an orderly progression, in which proliferating chondrocytes gradually differentiate into hypertrophic cells (56). Proliferating chondrocytes can be stained with alcian blue, and differentiated mature hypertrophic cells are stained with alizarin red (56). We compared the first appearance of ossification centers, which were stained red, at each stage in wild-type and Plk2-/- embryos and with those documented by Kaufman (26). The results showed that ossification occurred at the same time in most bones in Plk2-/- and normal embryos (Fig. 3). However, ossification on the third and fourth sternebrae and in the upper region of the xiphoid process was less advanced in all three Plk2-/- embryos from two litters. These data suggest that the Plk2 deletion did not significantly disrupt the overall development of the embryo.
|
94% of the weight of normal embryos at E16.5 and E17.5 and reached 86% at E18.5 (P < 0.05) (Table 1), suggesting a role for Plk2 in embryonic growth. Assessing the growth of the placenta showed that the average weight of placentas of Plk2-/- embryos was
70% (P < 0.05) of that of placentas of normal embryos at E16.5, and this difference was maintained until birth (Table 1). Mouse placenta is composed of a maternal (decidual) component and a component of embryonic origin, including a spongy layer of trophoblast cells, the labyrinth, and the chorionic plate. As the placenta matures, the labyrinthine zone increases in volume from E12.0 to E17.5 due to cell proliferation in the region and thereafter remains unchanged until birth (26). Histological analysis of placentas at E18.5 indicated that the labyrinthine zone of Plk2-/- embryos was significantly smaller than that of normal embryos, but the overall organization and structure, including the size of cells in this region, appeared to be normal (Fig. 4A). Because the size of the labyrinthine zone can be affected by cell death (apoptosis) and cell proliferation in the region, we used a TUNEL assay to assess cell death and phospho-histone H3 staining for cells in mitosis as an index for cell proliferation. The results showed no significant difference in the number of apoptotic cells per square millimeter in the labyrinthine zones of the placentas of normal and Plk2-/- embryos (Fig. 4B). On the other hand, the number of cells per square millimeter stained for phospho-histone H3 in the labyrinthine zones of Plk2-/- embryos was
64% of that in Plk2+/- embryos (P < 0.05) (Fig. 4C). These results provide evidence that Plk2 is involved in cell proliferation in vivo.
|
|
22 h, whereas Plk2-/- cells divided in
25 h. Thus, the cell cycle appears to be slightly delayed in the absence of Plk2. At passage 6, however, fibroblasts from both sources began to divide at about the same rate, perhaps because they reached the crisis stage. These results suggest a role for Plk2 in the cell cycle.
|
| DISCUSSION |
|---|
|
|
|---|
On the other hand, Plk2-/- mice have a growth rate comparable to that of normal mice, indicating that Plk2 is not required for postnatal growth. This is consistent with the results of a previous study showing that Plk2 message is generally absent from tissues of the adult mouse except in the brain and lung (47). The only other example we are aware of is the fact that the disruption of the gene encoding insulin-like growth factor II (IGF-II) exclusively affects embryonic growth (8). However, IGF-II exerts its effect early (E11.0), and the mutant mice are severely growth retarded at birth (60% of normal weight) (8).
Cell cycle analysis of cultured Plk2-/- embryonic fibroblasts indicates that these cells proliferate more slowly than cells expressing Plk2 and have delayed entry into S phase from G1. These results suggest a role for Plk2 in the cell cycle. Plk2 expression is limited to early G1 (36, 47), and Cdc25A is expressed in G1 and required for progression from G1 into S phase (21, 25). It is possible that Plk2 contributes to Cdc25A activation, but it is clearly not required. A previous study showed that overexpression of Plk2 induces changes in cell morphology and that Plk2 is expressed during the time when rounded cells are flattening and spreading after mitosis, which prompted speculation that Plk2 may be involved in these processes, as it can localize to the microtubule organizing center (36). Changes in the microtubule cytoskeleton appear to be necessary for cells to progress from G1 to S phase, as microtubule stabilization by taxol inhibits the initiation of DNA synthesis whereas microtubule depolymerization seems to prompt DNA synthesis (6, 7). However, primary Plk2-/- fibroblasts showed no significant change in cell morphology (data not shown) and were able to complete the cell cycle. Embryonic fibroblasts lacking cyclin D1 had a completely normal cell cycle, despite the fact that cyclin D1 knockout mice were small (14). Interestingly, knockin of cyclin E to replace the coding sequence of cyclin D1 completely rescued all phenotypes of cyclin D1 deletion (17). In mammalian cells, Plk2 and Plk3 show overlapping expression and cellular localization in G1 (4, 36, 57), and it is possible that Plk3 functions to complement Plk2 in Plk2-/- cells.
| ACKNOWLEDGMENTS |
|---|
This work is supported by a grant from the National Institutes of Health (GM59172) to R.L.E.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Carmena, M., M. G. Riparbelli, G. Minestrini, A. M. Tavares, R. Adams, G. Callaini, and D. M. Glover. 1998. Drosophila polo kinase is required for cytokinesis. J. Cell Biol. 143:659-671.
3. Charron, J., B. A. Malynn, P. Fisher, V. Stewart, L. Jeannotte, S. P. Goff, E. J. Robertson, and F. W. Alt. 1992. Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene. Genes Dev. 6:2248-2257.
4. Chase, D., Y. Feng, B. Hanshew, J. A. Winkles, D. L. Longo, and D. K. Ferris. 1998. Expression and phosphorylation of fibroblast-growth-factor-inducible kinase (Fnk) during cell-cycle progression. Biochem. J. 333:655-660.
5. Conn, C. W., R. F. Hennigan, W. Dai, Y. Sanchez, and P. J. Stambrook. 2000. Incomplete cytokinesis and induction of apoptosis by overexpression of the mammalian polo-like kinase, Plk3. Cancer Res. 60:6826-6831.
6. Crossin, K. L., and D. H. Carney. 1981. Evidence that microtubule depolymerization early in the cell cycle is sufficient to initiate DNA synthesis. Cell 23:61-71.[CrossRef][Medline]
7. Crossin, K. L., and D. H. Carney. 1981. Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor. Cell 2:341-350.
8. DeChiara, T. M., A. Efstratiadis, and E. J. Robertson. 1990. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 345:78-80.[CrossRef][Medline]
9. Descombes, P., and E. A. Nigg. 1998. The polo-like kinase Plx1 is required for M phase exit and destruction of mitotic regulators in Xenopus egg extracts. EMBO J. 17:1328-1335.[CrossRef][Medline]
10. do Carmo Avides, M., A. Tavares, and D. M. Glover. 2001. Polo kinase and Asp are needed to promote the mitotic organizing activity of centrosomes. Nat. Cell Biol. 3:421-424.[CrossRef][Medline]
11. Donohue, P. J., G. F. Alberts, Y. Guo, and J. A. Winkles. 1995. Identification by targeted differential display of an immediate early gene encoding a putative serine/threonine kinase. J. Biol. Chem. 270:10351-10357.
12. Duncan, P. I., N. Pollet, C. Niehrs, and E. A. Nigg. 2001. Cloning and characterization of Plx2 and Plx3, two additional Polo-like kinases from Xenopus laevis. Exp. Cell Res. 270:78-87.[CrossRef][Medline]
13. Efstratiadis, A. 1998. Genetics of mouse growth. Int. J. Dev. Biol. 42:955-976.[Medline]
14. Fantl, V., G. Stamp, A. Andrews, I. Rosewell, and C. Dickson. 1995. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 9:2364-2372.
15. Feng, Y., D. L. Longo, and D. K. Ferris. 2001. Polo-like kinase interacts with proteasomes and regulates their activity. Cell Growth Differ. 12:29-37.
16. Fero, M. L., M. Rivkin, M. Tasch, P. Porter, C. E. Carow, E. Firpo, K. Polyak, L.-H. Tsai, V. Broudy, R. M. Perlmutter, K. Kaushansky, and J. M. Roberts. 1996. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27Kip1-deficient mice. Cell 85:733-744.[CrossRef][Medline]
17. Geng, Y., W. Whoriskey, M. Y. Park, R. T. Bronson, R. H. Medema, T. Li, R. A. Weinberg, and P. Sicinski. 1999. Rescue of cyclin D1 deficiency by knockin cyclin E. Cell 97:767-777.[CrossRef][Medline]
18. Giroux, S., M. Tremblay, D. Bernard, J. F. Cardin-Girard, S. Aubry, L. Larouche, S. Rousseau, J. Huot, J. Landry, L. Jeannotte, and J. Charron. 1999. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr. Biol. 9:369-372.[CrossRef][Medline]
19. Golsteyn, R. M., H. A. Lane, K. E. Mundt, L. Arnaud, and E. A. Nigg. 1996. The family of polo-like kinases, p. 107-114. In L. Meijer, S. Guidet, and L. Vogel (ed.), Progress in cell cycle research, vol. 2. Plenum Press, New York, N.Y.
20. Hardy, C. F. J., and A. Pautz. 1996. A novel role for Cdc5p in DNA replication. Mol. Cell. Biol. 16:6775-6782.[Abstract]
21. Hoffman, I., G. Draetta, and E. Karsenti. 1994. Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J. 13:4302-4310.[Medline]
22. Holtrich, U., G. Wolf, J. Yuan, J. Bereiter-Hahn, T. Karn, M. Weiler, G. Kauselmann, M. Rehli, R. Andreesen, M. Kaufmann, D. Kuhl, and K. Strebhardt. 2000. Adhesion induced expression of the serine/threonine kinase Fnk in human macrophages. Oncogene 19:4832-4839.[CrossRef][Medline]
23. Hu, F., Y. Wang, D. Liu, Y. Li, J. Oin, and S. J. Elledge. 2001. Regulation of the Bub2/Bfa1 GAP complex by Cdc5 and cell cycle checkpoints. Cell 107:655-665.[CrossRef][Medline]
24. Jang, Y. J., S. Ma, Y. Terada, and R. L. Erikson. 2002. Phosphorylation of threonine-210 and the role of serine-137 in the regulation of mammalian polo-like kinase. J. Biol. Chem. 277:44115-44120.
25. Jinno, S., K. Suto, A. Nagata, M. Igarashi, Y. Kanaoka, H. Nojima, and H. Okayama. 1994. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J. 13:1549-1556.[Medline]
26. Kaufman, M. H. 1992. The atlas of mouse development. Academic Press Ltd., London, United Kingdom.
27. Kauselmann, G., M. Weiler, P. Wulff, S. Jessberger, U. Konietzko, J. Scafidi, U. Staubli, J. Bereiter-Hahn, K. Strebhardt, and D. Kuhl. 1999. The polo-like protein kinases Fnk and Snk associate with a Ca2+- and integrin-binding protein and are regulated dynamically with synaptic plasticity. EMBO J. 18:5528-5539.[CrossRef][Medline]
28. Kiyokawa, H., R. D. Kineman, K. O. Manova-Todorova, V. C. Soares, E. S. Hoffman, M. Ono, D. Khanam, A. C. Hayday, L. A. Frohman, and A. Koff. 1996. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 85:721-732.[CrossRef][Medline]
29. Kotani, S., S. Tugendreich, M. Fujii, P.-M. Jorgensen, N. Watanabe, C. Hoog, P. Hieter, and K. Todokoro. 1998. PKA and MPF-activated polo-like kinase regulate anaphase-promoting complex activity and mitosis progression. Mol. Cell 1:371-380.[CrossRef][Medline]
30. Kumagai, A., and W. G. Dunphy. 1996. Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Science 273:1377-1380.[Abstract]
31. Lane, H., and E. A. Nigg. 1997. Cell-cycle control: POLO-like kinases join the outer circle. Trends Cell. Biol. 7:63-68.[Medline]
32. Lane, H. A., and E. A. Nigg. 1996. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J. Cell Biol. 135:1701-1713.
33. Lee, K. S., and R. L. Erikson. 1997. Plk is a functional homolog of Saccharomyces cerevisiae Cdc5, and elevated Plk activity induces multiple septation structures. Mol. Cell. Biol. 17:3408-3417.[Abstract]
34. Lin, C. Y., M. L. Madsen, F. R. Yarm, Y. J. Jang, X. Liu, and R. L. Erikson. 2000. Peripheral Golgi protein GRASP65 is a target of mitotic polo-like kinase (Plk) and Cdc2. Proc. Natl. Acad. Sci. USA 97:12589-12594.
35. Liu, X., and R. L. Erikson. 2002. Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc. Natl. Acad. Sci. USA 99:8672-8676.
36. Ma, S., M.-Y. Liu, Y.-L. O. Yuan, and R. L. Erikson. 2003. The serum-inducible kinase is a G1 polo-like kinase that is inhibited by the calcium- and integrin-binding protein CIB. Mol. Cancer Res. 1:376-384.
37. Nakayama, K., N. Ishida, M. Shirane, A. Inomata, T. Inoue, N. Shishido, I. Horii, D. Y. Loh, and K.-I. Nakayama. 1996. Mice lacking p27kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707-720.[CrossRef][Medline]
38. Ohkura, H., I. M. Hagan, and D. M. Glover. 1995. The conserved Schizosaccharomyces pombe kinase plo1, required to form a bipolar spindle, the actin ring, and septum, can drive septum formation in G1 and G2 cells. Genes Dev. 9:1059-1073.
39. Ouyang, B., H. Pan, L. Lu, J. Li, P. Stambrook, B. Li, and W. Dai. 1997. Human Prk is a conserved protein serine/threonine kinase involved in regulating M phase functions. J. Biol. Chem. 272:28646-28651.
40. Qian, Y.-W., E. Erikson, C. Li, and J. L. Maller. 1998. Activated polo-like kinase Plx1 is required at multiple points during mitosis in Xenopus laevis. Mol. Cell. Biol. 18:4262-4271.
41. Qian, Y.-W., E. Erikson, and J. L. Maller. 1999. Mitotic effects of a constitutively active mutant of the Xenopus polo-like kinase Plx1. Mol. Cell. Biol. 19:8625-8632.
42. Qian, Y. W., E. Erikson, F. E. Taieb, and J. L. Maller. 2001. The polo-like kinase Plx1 is required for activation of the phosphatase Cdc25C and cyclin B-Cdc2 in Xenopus oocytes. Mol. Biol. Cell. 12:1791-1799.
43. Ramirez-Solis, R., A. C. Davis, and A. Bradley. 1993. Gene targeting in embryonic stem cells. Methods Enzymol. 225:855-878.[Medline]
44. Sanchez, Y., J. Bachant, H. Wang, F. Hu, D. Liu, M. Tetzlaff, and S. J. Elledge. 1999. Control of the DNA damage checkpoint by chk1 and rad53 protein kinases through distinct mechanisms. Science 286:1166-1171.
45. Shirayama, M., W. Zachariae, R. Ciosk, and K. Nasmyth. 1998. The Polo-like kinase Cdc5p and the WD-repeat protein Cdc20p/fizzy are regulators and substrates of the anaphase promoting complex in Saccharomyces cerevisiae. EMBO J. 17:1336-1349.[CrossRef][Medline]
46. Sicinski, P., J. L. Donaher, S. B. Parker, T. Li, A. Fazeli, G. Humphrey, S. Z. Haslam, R. T. Bronson, S. J. Elledge, and R. A. Weinberg. 1995. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621-630.[CrossRef][Medline]
47. Simmons, D. L., B. G. Neel, R. Stevens, G. Evett, and R. L. Erikson. 1992. Identification of an early-growth-response gene encoding a novel putative protein kinase. Mol. Cell. Biol. 12:4164-4169.
48. Smits, V. A., R. Klompmaker, L. Arnaud, G. Rijksen, E. A. Nigg, and R. H. Medema. 2000. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat. Cell Biol. 2:672-676.[CrossRef][Medline]
49. Song, S., and K. S. Lee. 2001. A novel function of Saccharomyces cerevisiae CDC5 in cytokinesis. J. Cell Biol. 152:451-470.
50. Sumara, I., E. Vorlaufer, P. T. Stukenberg, O. Kelm, N. Redemann, E. A. Nigg, and J. M. Peters. 2002. The dissociation of cohesin from chromosomes in prophase is regulated by polo-like kinase. Mol. Cell 9:515-525.[CrossRef][Medline]
51. Sunkel, C. L., and D. M. Glover. 1988. polo, a mitotic mutant of Drosophila displaying abnormal spindle poles. J. Cell Sci. 89:25-38.
52. Sutterlin, C., C. Y. Lin, Y. Feng, D. K. Ferris, R. L. Erikson, and V. Malhotra. 2001. Polo-like kinase is required for the fragmentation of pericentriolar Golgi stacks during mitosis. Proc. Natl. Acad. Sci. USA 98:9128-9132.
53. Toczyski, D. P., D. J. Galgoczy, and L. H. Hartwell. 1997. CDC5 and CKII control adaptation to the yeast DNA damage checkpoint. Cell 90:1097-1106.[CrossRef][Medline]
54. Todaro, G. J., and H. Green. 1963. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J. Cell Biol. 17:299-313.
55. Toyoshima-Morimoto, F., E. Taniguchi, N. Shinya, A. Iwamatsu, and E. Nishida. 2001. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 410:215-220.[CrossRef][Medline]
56. Vortkamp, A., K. S. Lee, B. Lanske, G. V. Serge, H. M. Kronenberg, and C. J. Tabin. 1996. Regulation of rate of cartilage differentiation by Indian Hedgehog and PTH-related protein. Science 273:613-621.[Abstract]
57. Wang, O., S. Xie, J. Chen, K. Fukasawa, U. Naik, F. Traganos, Z. Darzvnkiewicz, M. Jhanwar-Unival, and W. Dai. 2002. Cell cycle arrest and apoptosis induced by human Polo-like kinase 3 is mediated through perturbation of microtubule integrity. Mol. Biol. Cell. 22:3450-3459.
58. Xie, S., H. Wu, Q. Wang, J. P. Cogswell, I. Husain, C. Conn, P. Stambrook, M. Jhanwar-Uniyal, and W. Dai. 2001. Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway. J. Biol. Chem. 276:43305-43312.
59. Yu, J., T. J. Carrol, and A. P. McMahon. 2002. Sonic hedgehog regulates proliferation and differentiation of mesenchymal cells in the mouse metanephric kidney. Development 129:5301-5312.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|